China Resources Double-Crane Pharmaceutical Co Ltd banner
C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 18.05 CNY -0.44% Market Closed
Market Cap: ¥18.7B

China Resources Double-Crane Pharmaceutical Co Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Resources Double-Crane Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Cash from Operating Activities
¥1.5B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
8%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
¥4.8B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
¥11.2B
CAGR 3-Years
107%
CAGR 5-Years
27%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
¥4.6B
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
8%
Zhejiang Nhu Co Ltd
SZSE:002001
Cash from Operating Activities
¥8.8B
CAGR 3-Years
26%
CAGR 5-Years
23%
CAGR 10-Years
25%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
¥4.1B
CAGR 3-Years
N/A
CAGR 5-Years
171%
CAGR 10-Years
N/A
No Stocks Found

China Resources Double-Crane Pharmaceutical Co Ltd
Glance View

Market Cap
18.7B CNY
Industry
Pharmaceuticals

In the dynamic landscape of China's pharmaceutical industry, China Resources Double-Crane Pharmaceutical Co Ltd emerges as a key player. It traces its roots back to the early 20th century, embodying a rich history of transformation and innovation. The company seamlessly integrates research, development, production, and sales, making it a formidable force in the healthcare sector. Primarily, it focuses on the production of chemical and biological drugs, catering to a wide range of therapeutic areas such as cardiovascular diseases, anti-infection solutions, and nutritional drugs. Through its comprehensive network, the company not only retains a robust domestic presence but also pushes its products into international markets, driving its revenue growth. Double-Crane's business model thrives on a blend of strategic partnerships and a strong emphasis on R&D. By collaborating with top research institutes and leveraging cutting-edge technology, it innovates new products to meet the rising demands of modern healthcare. The company’s substantial investment in R&D has allowed it to build a strong pipeline of proprietary drugs, ensuring a steady stream of products to boost its market position. With a keen eye on market trends and patient needs, China Resources Double-Crane continually optimizes its production processes and expands its distribution channels. This methodical approach enables the company to enhance its profitability while propelling it as a leader in the pharmaceutical industry.

Intrinsic Value
27.78 CNY
Undervaluation 35%
Intrinsic Value
Price ¥18.05
C

See Also

What is China Resources Double-Crane Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.5B CNY

Based on the financial report for Dec 31, 2025, China Resources Double-Crane Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 1.5B CNY.

What is China Resources Double-Crane Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
8%

Over the last year, the Cash from Operating Activities growth was -18%. The average annual Cash from Operating Activities growth rates for China Resources Double-Crane Pharmaceutical Co Ltd have been 2% over the past three years , 2% over the past five years , and 8% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett